8 Things to Know About Rasayan Labs, the Startup Building an AI Operating System for Drug Discovery

1. One platform replaces your entire tool stack.

Rasayan Labs has built a unified AI operating system for small molecule drug discovery. Retrosynthesis, ADMET prediction, patent searching, literature review, and compound intelligence all live in a single environment. No more switching between disconnected tools and losing context along the way. 

2. Their AI models are ranked among the best in the world.

Rasayan's toxicity models rank #5 globally on the Tox21 leaderboard, placing the company alongside OpenAI, Stanford, and MIT. That ranking is backed by 105+ specialized AI models, 1.3 billion indexed reactions, and 118 million indexed patents powering the platform. 

3. They search 1.3 trillion molecules.

The platform's compound intelligence engine gives researchers access to 1.3 trillion virtual molecules, searchable by name, structure, image, or hand-drawn sketch. Each molecule comes with over 1,400 ADMET property predictions, from hERG cardiotoxicity, logD, solubility, pKA, and more. 

4. They run their own drug discovery pipeline.

Rasayan currently has 19 novel compounds in synthesis across internal programs targeting inflammation (COX-2/mPGES). Running their own science means every feature is validated by real research, not just benchmarks. The company has also begun onboarding biotech and pharma partners to run pilot drug discovery programs across additional therapeutic areas. 

5. They identified 23 dual-target inhibitors in under a month.

The platform's speed is already producing published results. Rasayan identified 23 dual-target inhibitors for inflammation in under 30 days. 

6. They cut RFP cycles from 22 days to 2.

Drug discovery bottlenecks extend well beyond the lab. Rasayan built RFP automation directly into the platform, compressing proposal response timelines by over 90%. A single trigger auto-runs six chemistry modules (Ames, PDE, pKA), extracts reagents and reaction conditions from scientific procedures, digitizes the full synthesis route, and generates raw material requirements automatically. For business development teams, that speed is becoming a competitive advantage in itself. 

7. 2,400+ researchers are already on the platform.

Rasayan reports a growing user base spanning pharmaceutical companies, biotechs, and academic institutions. Researchers are already using OCSR.ai, Rasayan's free chemical structure search engine, to look up any compound and download reports containing related patent filings, literature references, and toxicity predictions.

8. They have institutional backing from one of India's top research universities.

Rasayan has signed a memorandum of understanding with the Institute of Chemical Technology (ICT) Mumbai, India's 6th-ranked pharmacy school. Through the partnership, Professor Prashant Kharkar, a leading expert in medicinal chemistry and computer-aided drug design, contributes academic research infrastructure and domain expertise directly to Rasayan's platform development and validation pipeline. 

For more information or to book a demo, visit rasayan.ai.